Ischemic Heart Disease (IHD) Drugs Market Report by Disease Class (Angina Pectoris, Myocardial Infarction), Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), and Region 2025-2033

Ischemic Heart Disease (IHD) Drugs Market Report by Disease Class (Angina Pectoris, Myocardial Infarction), Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A1413

Market Overview:

The global ischemic heart disease (IHD) drugs market size reached USD 6.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 9.3 Billion by 2033, exhibiting a growth rate (CAGR) of 3.73% during 2025-2033.

Report Attribute
 Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024 USD 6.6 Billion
Market Forecast in 2033 USD 9.3 Billion
Market Growth Rate (2025-2033) 3.73%


Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels or sudden closure and narrowing of coronary arteries by atheroma. The disease is often characterized by chronic chest pain and severe discomfort and can be fatal if left untreated. Various drugs are used to treat IHD depending on the intensity of the case. For instance, if cholesterol-modifying medication decreases cholesterol levels in the blood, then aspirin is prescribed to reduce clotting tendencies of the blood, and beta blockers are utilized to lower the heart rate and decrease blood pressure. IHD drugs also include calcium channel blockers and ranolazine that improve the efficiency of beta blockers and prevent further progression of coronary disease.

The growing inclination of the masses towards interventional medical procedures along with extensive utilization of anti-anginal medications for the treatment of IHD is one of the key factors driving the market growth. IHD drugs are being incorporated in cardiological treatment procedures such as angioplasty, atherectomy and balloon angioplasty to ensure a healthy recovery and prevent relapse in the future. Additionally, rising consumer awareness regarding the benefits of scheduled administration of these drugs is also creating a significant impact on their demand. Lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are also leading to an increasing prevalence of cardiovascular diseases. Furthermore, the expanding population of geriatrics around the globe, who are severely prone to heart ailments, is also boosting the demand for IHD drugs.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global ischemic heart disease (IHD) drugs market report, along with forecasts at the global and regional level from 2025-2033. Our report has categorized the market based on disease class and drug class.

Breakup by Disease Class:

  • Angina Pectoris
  • Myocardial Infarction


Breakup by Drug Class:

  • Anti-Dyslipidemic Drugs
  • Calcium Channel Blockers
  • Beta-Blockers
  • ACE Inhibitors
  • ARBs
  • Vasodilators
  • Antithrombotic Agents


Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America


Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Disease Class, Drug Class, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Bayer AG, Eli Lilly and Company, Novartis International AG, Pfizer, Inc., Sanofi S.A., Actelion Pharmaceuticals Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Amgen Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co., and Eisai Co., Ltd.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


Key Questions Answered in This Report:

  • How has the global ischemic heart disease (IHD) drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global ischemic heart disease (IHD) drugs market?
  • What is the breakup of the market based on the disease class?
  • What is the breakup of the market based on the drug class?
  • What are the key regional markets in the global ischemic heart disease (IHD) drugs industry?
  • What are the various stages in the value chain of the global ischemic heart disease (IHD) drugs industry?
  • What are the key driving factors and challenges in the global ischemic heart disease (IHD) drugs industry?
  • What is the structure of the global ischemic heart disease (IHD) drugs industry and who are the key players?
  • What is the degree of competition in the global ischemic heart disease (IHD) drugs industry?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Ischemic Heart Disease (IHD) Drugs Market Report by Disease Class (Angina Pectoris, Myocardial Infarction), Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials